Analyst consensus rating
Gain Therapeutics Analyst Rating: Strong Buy
GANX is rated Strong Buy by 5 analysts with a $7.20 target. As of 2026-09-02.
Direct answer
Gain Therapeutics's consensus rating is Strong Buy.
5 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $7.20.
Forecast evidence checked September 2, 2026.
Get free Gain Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $1.82
- Average price target
- $7.20
- High price target
- $8.00
- Low price target
- $5.00
- Low target gap
- +174.7%
- Target upside
- +295.6%
- High target gap
- +339.6%
- Target range width
- 164.8%
- Consensus rating
- Strong Buy
- Analysts
- 5
- Evidence date
- September 2, 2026
- Valid through
- September 9, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Gain Therapeutics?
Gain Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $7.20.
How far are Gain Therapeutics's low and high targets from the recorded price?
The low target implies +174.7%, while the high target implies +339.6%.
How many analysts are included in Gain Therapeutics's consensus?
The verified consensus includes 5 analysts.
How is Gain Therapeutics's target upside or downside calculated?
The average target of $7.20 is divided by the recorded price of $1.82, then one is subtracted to produce +295.6%. This does not guarantee a future return.
When was Gain Therapeutics's analyst forecast verified?
The data was verified on 2026-09-02. The dataset is valid through 2026-09-09.